2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3374 Outcomes and characteristics of acute myeloid leukemia harboring KMT2A partial tandem duplications (PTD)

Wei Ying Jen, BM BCh, FRCPath, Guilin Tang, MD, PhD,FACMG2, Abhishek Maiti, MBBS3, Sean M Post4, Alex Bataller, MD, PhD5, Guillermo Montalban-Bravo, MD6, Tapan Kadia I, MD7, Nicholas Short, MD8, Musa Yilmaz, MD9, Alexandre Bazinet, MD, MSc10, Elias Jabbour, MD11, Ian Bouligny, M.D.12, Eitan Kugler, MD PhD13, Jennifer Marvin-Peek, MD14, Hannah Goulart, MD15, Koichi Takahashi, MD,PhD16, Sanam Loghavi, MD17, Farhad Ravandi, MD18, Guillermo Garcia-Manero, MD19, Naval Daver, MD20, Ghayas C. Issa, MD21, Courtney DiNardo, MD, MSCE22
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction

KMT2A-PTD results from intragenic duplications spanning exons 2-11 of KMT2A, producing an elongated KMT2A protein carrying a duplicated N-terminal region with preserved histone methyltransferase capacity. KMT2A-PTD target genes include HOX genes and MYC, and PTDs are implicated in maintaining leukemia proliferation. The prognostic significance of KMT2A-PTD is conflicting, with older data suggesting an adverse prognosis, especially within the context of a diploid karyotype. Data in the venetoclax era are lacking. We aimed to describe the landscape of myeloid malignancies harboring KMT2A-PTD and compare outcomes of cases with and without KMT2A-PTD in newly diagnosed (ND) acute myeloid leukemia (AML).

Methods

This was a single center, retrospective study. Consecutive cases of KMT2A-PTD were identified by optical genome mapping (OGM) and/or NGS-based RNA-sequencing (RNA-seq). The control cohort comprised a contemporary ND AML cohort without KMT2A-PTD interrogated by OGM and/or RNA-seq, and without core binding leukemia or NPM1mt AML (mutually exclusive with KMT2A-PTD). Univariate and multivariate analyses were conducted using Cox regression.

Results

We identified 81 cases of KMT2A-PTD, 52 ND and 29 relapsed/refractory (RR). In the ND group, the underlying diagnosis was AML in 39/52 (75%), chronic myelomonocytic leukemia in 13%, myelodysplastic syndrome in 10% and mixed phenotype acute leukemia in 2%. The median age was 70 (range, 36-87); 12% had prior exposure to hypomethylating agents (HMA). Cytogenetics were diploid in 48% and complex in 13%. The most frequent co-occurring mutations were in ASXL1 (19%), FLT3 (48%, ITD in 35%), U2AF1 (25%), NRAS (19%), KRAS (13%), IDH2 (12%), and IDH1 (10%). No KMT2A-PTD patients had an NPM1 mutation. At presentation, median white blood cell counts and platelets were 6.25x109/L (range, 0.4-179) and 63x109/L (range, 8-993), respectively. Pts were treated with intensive chemotherapy (IC, 19%) or low-intensity therapy (LIT, 79%); 1 pt received best supportive care. Venetoclax was incorporated into the treatment regimen in 81%, FLT3 inhibitor (FLT3i) use in 33% and IDH inhibitors (IDHi) in 12%.

KMT2A-PTD was detected in 10% of ND AML.  By ELN 2022, 37% were intermediate and 63% were adverse risk. In pts with ND AML with KMT2A-PTD (n = 39), compared with the control cohort (n = 268), KMT2A-PTD was associated with intermediate risk cytogenetics (84% vs 43%, p <0.0001) and signaling (68% vs 44%, p=0.02) and DNA methylation (76 vs 38% p<0.0001) mutations. The proportion of cases with complex cytogenetics (16% vs 45%, p=0.003) and TP53 mutations (8% vs 35%, p =0.004) were lower. The proportions of controls treated with IC and LIT with or without venetoclax were similar.

KMT2A-PTD was associated with an overall response rate of 84% (95% CI, 70-93) and a composite CR (CRc) rate of 82% (95% CI, 67-91). The median OS was 29 months (95% CI, 11-NE) vs 13 months (95% CI, 11-19) in the control cohort (p=0.07); the 18-month OS was 56% (95% CI, 41-76) vs 45% (95% CI, 39-52). On multivariate analysis of all patients, KMT2A-PTD had no impact on OS; prior HMA exposure, adverse cytogenetics and TP53 mutations were predictive of worse outcome, and IC and VEN use associated with better OS. The mEFS was 24 months (95% CI, 8.1-NE) compared with 7.7 months (95% CI, 6-10) for the control cohort (p=0.03), with an 18-month EFS of 55% (95% CI, 41-75) vs 34% (95% CI, 29-41). The association with better EFS was not significant on multivariable analysis. In KMT2A-PTD responders, the median duration of response was 53 months, with 82% (95% CI, 68-98) still maintaining a response at 18 months.

Conclusion

KMT2A-PTD are common in ND AML and are associated with an intermediate prognosis. The presence of KMT2A-PTD does not appear to influence prognosis and suggests that AML outcome is driven by established prognostic factors. The outcomes of KMT2A-PTD patients reported here appear generally favorable as compared to historical reports, which may be due to improvements in supportive care and / or the incorporation of venetoclax into frontline treatment regimens.
Wei Ying Jen, BM BCh, FRCPath: No relevant conflicts of interest to declare.